Nancy Bradish Myers
Contributor
Nancy Bradish Myers is a Washington-based attorney with expertise in health care policy development, regulatory strategy, government relations and political analysis. She is the President of Catalyst Healthcare Consulting, Inc. a seasoned health care consulting firm that provides clients with a range of services from regulatory intelligence, strategic policy analysis and development assistance, to regulatory coaching in order allow biopharmaceutical, medical device companies, trade associations, investors, and patient advocacy organizations become more effective, efficient achieving their objectives. Ms. Myers is very goal oriented and enjoys helping clients strategically expand their sphere of influence in the health policy and regulatory space.
Latest From Nancy Bradish Myers
Biden’s FDA Commissioner Playbook: Build On COVID Innovations To Modernize Agency
Unintended silver lining of pandemic-generated innovation has brought the agency to an opportunistic fork in the road, and the commissioner choice will be consequential in determining the path forward.
Biden’s FDA Commissioner Playbook: Build On COVID Innovations To Modernize Agency
Unintended silver lining of pandemic-generated innovation has brought the agency to an opportunistic fork in the road, and the commissioner choice will be consequential in determining the path forward.
Scientific Wave Pushes CBER Into Brighter Light
What are US regulators doing to prepare for adequate review of the upcoming wave of gene therapy applications, and what other actions could CBER take to ensure it is able to facilitate the expected onslaught of breakthroughs in this field? Consultant Nancy Bradish Myers weighs in.
How A Rapid, Well-Messaged US FDA Offense Is Driving Spectators To Their Feet And Twitter Accounts
Consultant Nancy Bradish Myers examines why US FDA seems to be accomplishing so much under Commissioner Gottlieb’s leadership and how this could inform future leadership selections.
How a Rapid and Well-Messaged US FDA Offense Is Driving Spectators to Their Feet and Twitter Accounts
Consultant examines why FDA seems to be accomplishing so much under FDA Commissioner Gottlieb’s leadership and how this could inform future leadership selections.
UFA Creep: Time to Apply the Brake?
FDA’s user fee programs continue to proliferate. The new resources are great, but FDA and its stakeholders need to think carefully before going even further down this road.